This product works as a proteasome inhibitor, disrupting protein degradation in malignant cells and promoting apoptosis.
Recommended for:
patients with multiple myeloma
individuals with mantle cell lymphoma
cases resistant to conventional chemotherapy
as part of combination therapy
Multiple myeloma, mantle cell lymphoma
Bortenat is administered intravenously or subcutaneously based on a personalised protocol defined by an oncologist. Dosage is weight-based and depends on the patient's condition. Strict adherence to the treatment protocol is required.
Contraindications:
Hypersensitivity to Bortezomib or boron
Pregnancy and lactation
Severe hepatic impairment
Severe active infections
Side Effects:
Peripheral neuropathy
Nausea, vomiting, diarrhoea
Myelosuppression (anaemia, thrombocytopenia, leukopenia)
Fever, fatigue
Injection site reactions
